LYTGOBI

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug LYTGOBI contains one active pharmaceutical ingredient (API):

1 Futibatinib UNII 4B93MGE4AL - FUTIBATINIB

Constitutive fibroblast growth factor receptor (FGFR) signalling can support the proliferation and survival of malignant cells. Futibatinib is a tyrosine kinase inhibitor that irreversibly inhibits FGFR 1, 2, 3, and 4 by covalent binding. Read about Futibatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LYTGOBI Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EN04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
Discover more medicines within L01EN04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3035090, 3035102, 3035113
Country: FR	Base de données publique des médicaments	Identifier(s): 68552628
Country: IT	Agenzia del Farmaco	Identifier(s): 050756016, 050756028, 050756030
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097365, 1097366, 1097367
Country: US	FDA, National Drug Code	Identifier(s): 64842-0120